Reported 7 months ago
A survey by the International Foundation of Employee Benefit Plans reveals that about one-third of U.S. employer health plans now provide coverage for GLP-1 drugs, such as Wegovy and Zepbound, for both diabetes management and weight loss. The use of these drugs for weight loss has increased, comprising 8.9% of employers' medical claims spending in 2024 from 6.9% in 2023. Global sales for GLP-1 drugs are projected to reach $150 billion annually by the early 2030s, but resistance from insurers remains a limiting factor for drugmakers despite high demand and efficacy.
Source: YAHOO